Cobra Biologics Companies

Cobra and Karolinska Institutet said March 30 they were awarded €3 million ($3.3 million) in emergency funding through the EU’s Horizon 2020 funding program for R&D and Phase I clinical trial testing of a DNA vaccine against COVID-19, as part of the OPENCORONA consortium. In addition to Karolinska Institutet, partners in the consortium also include Karolinska University Hospital, the Public Health Agency of Sweden (FoHM), IGEA, Adlego, and Giessen University.
Technology: COVID
Industry: Vaccine/Drug
Headquarters: United Kingdom
Founded Date: 1992
Employees Number: 501-1000
Funding Status: N/A

Visit Website
@CobraBiologics
Register and Claim Ownership